FDA approves first generic liraglutide once-daily injection
The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals) ...
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
MedPage Today5d
First Generic of Once-Daily GLP-1 Injection Approved for Diabetes
The FDA has approved the first generic form of liraglutide (Victoza), a once-daily injectable for improving glycemic control ...
FDA approves GLP-1 generic for Type 2 diabetes
The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who ...
healthday on MSN2d
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
SiliconIndia5d
Biocon and Zentiva Gain EU Approval for Generic Liraglutide
Biocon and Zentiva Gain EU Approval for Generic Liraglutide - Biocon Limited , in collaboration with its European partner ...
CNN5d
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...
Medscape5d
FDA Approves Second Generic Daily GLP-1 Drug for T2D
The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...
ConsumerAffairs3d
FDA approves generic GLP-1 drug to treat type 2 diabetes
The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...
Is Eli Lilly Stock a Buy?
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
Biocon, Zentiva get approval for diabetes tratement drug Liraglutide for EU region
Biocon said that the company and Zentiva, its European partner, have received a de-centralized procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU).